Exosome RNA Exosome RNA Research & Industry News
Extracellular vesicles, including exosomes, are tiny particles naturally released by cells that can carry biological cargo such as RNA and proteins. Because they are already used by the body for communication between cells, scientists are exploring how to use them as delivery vehicles for drugs. A related group of particles, called plant-derived exosome-like nanoparticles, or PELNs, come from edible plants and may offer advantages for large-scale and oral delivery.
Scientists at Jiaxing University compared animal-derived exosomes and plant-derived nanoparticles from a drug development perspective. Instead of focusing only on biology, the work looks at how these particles behave as pharmaceutical delivery systems.
One of the key ideas is that the effectiveness of these vesicles depends heavily on what they carry. Their cargo, such as microRNAs or proteins, determines how they influence cells. However, successful therapy also depends on how well these particles can survive in the body, reach the right tissues, enter cells, and release their cargo in the correct location.
The researchers highlight several important delivery scenarios. These include delivering drugs through the bloodstream, crossing the blood-brain barrier, surviving digestion for oral delivery, and targeting tumors. Each of these environments presents different challenges, and the composition of the vesicles plays a major role in how well they perform.
Another important focus is engineering. Scientists can modify these vesicles in different ways to improve their performance. For example, they can load specific therapeutic molecules into them, adjust their surface to better target certain cell types, or enrich them with beneficial cargo. However, these modifications also introduce challenges related to safety, consistency, and large-scale manufacturing.
Plant-derived nanoparticles are especially interesting because they may be easier to produce in large quantities and could potentially be taken orally. This opens the door to more accessible and scalable therapies compared to traditional biologics.
To move these technologies toward clinical use, the researchers emphasize the need for standardized measurements, better understanding of how the particles behave in the body, reliable potency testing, and consistent manufacturing under regulatory guidelines.
Overall, extracellular vesicles and exosome-like nanoparticles represent a promising platform for drug delivery. By focusing on both cargo and delivery behavior, researchers are building a clearer path toward real-world therapeutic applications.
